| Literature DB >> 31185622 |
Jin-Ming Meng1, Shi-Yu Cao2, Xin-Lin Wei3, Ren-You Gan4, Yuan-Feng Wang5, Shu-Xian Cai6, Xiao-Yu Xu7, Pang-Zhen Zhang8, Hua-Bin Li9.
Abstract
Diabetes mellitus has become a serious and growing public health concern. It has high morbidity and mortality because of its complications, such as diabetic nephropathy, diabetic cardiovascular complication, diabetic neuropathy, diabetic retinopathy, and diabetic hepatopathy. Epidemiological studies revealed that the consumption of tea was inversely associated with the risk of diabetes mellitus and its complications. Experimental studies demonstrated that tea had protective effects against diabetes mellitus and its complications via several possible mechanisms, including enhancing insulin action, ameliorating insulin resistance, activating insulin signaling pathway, protecting islet β-cells, scavenging free radicals, and decreasing inflammation. Moreover, clinical trials also confirmed that tea intervention is effective in patients with diabetes mellitus and its complications. Therefore, in order to highlight the importance of tea in the prevention and management of diabetes mellitus and its complications, this article summarizes and discusses the effects of tea against diabetes mellitus and its complications based on the findings from epidemiological, experimental, and clinical studies, with the special attention paid to the mechanisms of action.Entities:
Keywords: complication; diabetes mellitus; epigallocatechin-3-gallate; mechanisms; polyphenol; tea
Year: 2019 PMID: 31185622 PMCID: PMC6617012 DOI: 10.3390/antiox8060170
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Figure 1Chemical structures of main catechins in tea.
The relationship of tea consumption and diabetes mellitus by epidemiological studies.
| Diseases | Tea Type | Study Type | Participants | Dose | Results | Ref. |
|---|---|---|---|---|---|---|
| Diabetes mellitus | Tea | Prospective cohort study | Individuals (N = 7006) aged 32–88 without diabetes mellitus | N/A | The consumption of tea showed an decreased risk of diabetes mellitus for nonelderly adults who had previously lost weight. | [ |
| Diabetes mellitus | Green tea | Cohort study | Elderly Japanese men and women (N = 11,717) | N/A | Women with a higher intake of green tea had a lower risk of diabetes mellitus. | [ |
| Diabetes mellitus | Black Tea | placebo-controlled study | Total participants (N = 24) aged 20–60 | N/A | Drinking black tea could decrease postprandial blood sugar. | [ |
| T2DM | Tea | Population-based cohort study | Danish non-diabetic women with singleton pregnancies (N = 71,239) | 8 cups per day | The consumption of tea showed protective effects against T2DM (RR = 0.55, 95% CI (0.55, 1.08)). | [ |
| T2DM | Tea | Prospective Cohort study. | African American women (N = 46,906) | N/A | The consumption of tea wasn’t associated with T2DM. | [ |
| T2DM | Tea | Prospective cohort study. | British men (N = 4055) and women (N = 1768) | N/A | Tea intake was beneficial for DM (HR = 0.66, 95% CI (0.61, 1.22)), | [ |
| T2DM | Tea | Case-Control study | Newly diagnosed diabetic cases (N = 599) | 2 cups per day | Habitual drinking tea could reduce the risk of T2DM (OR = 0.66, 95% CI (0.49–0.89)). | [ |
| T2DM | Tea | Case-Cohort Study | Total participants (N = 16,835) | ≥1 cups per day | The consumption of tea has negative relation with T2DM | [ |
| T2DM | Tea | Meta-analysis | Total participants (N = 545,517); | N/A | The consumption of tea has negative relation with T2DM ( | [ |
| T2DM | Tea | Meta-analysis | N/A | N/A | Drinking tea daily (≥3 cups/day) is associated with a lower risk of T2DM (RR = 0.84, 95% CI (0.73, 0.97)) | [ |
| T2DM | Tea | Meta-analysis | Total participants (N = 324,141); | N/A | Tea consumption a ≥4 cups per day may lower the risk of T2DM. | [ |
| T2DM | Tea | Meta-analysis | Total participants (N = 457,922) | N/A | The consumption of tea was associated with reduced risk of diabetes mellitus. | [ |
| T2DM | Tea | Descriptive study | Total participants (N = 940) | N/A | Long-term tea intake had effects on the prevention and treatment of diabetes mellitus. | [ |
| T2DM | Green tea | Meta-analysis | N/A | N/A | The consumption of tea wasn’t associated with T2DM. | [ |
| T2DM | Green tea | Meta-analysis | N/A | N/A | Tea or tea extract could maintain stable fasting insulin level in patients with T2DM. | [ |
| T2DM | Green tea | Meta-analysis | Total participants (N = 510) | N/A | Green tea had no effect on insulin sensitivity and blood glucose control. | [ |
| T2DM | Black tea | Cohort study. | Total participants (N = 36,908) | ≥1 cups per day | Black tea had association with T2DM (RR = 0.86, 95% CI (0.74, 1.00)). | [ |
| T2DM | Oolong tea | Prospective cohort study. | Japanese male workers (N = 4975) | ≥1 cups per day | Long-term consumption of oolong tea may be a predictive factor for new onset diabetes mellitus. | [ |
| Diabetic nephropathy | Green tea | Cohort study | Diabetic patients (N = 42) | N/A | Green tea extract could reduce proteinuria in diabetic patients. | [ |
| Diabetic Retinopathy | Green tea | Case-Control Study | Cases with diabetic retinopathy (N = 100) and diabetic patients without retinopathy (N = 100) | N/A | Long-term drinking green tea had preventive effects on diabetic retinopathy (OR = 0.49, 95% CI (0.26–0.90)). | [ |
Abbreviations: T2DM, type 2 diabetes mellitus; N/A, not available.
Figure 2The molecular mechanisms of EGCG against diabetes mellitus and its complications. EGCG has shown effects against T2DM by improving IR, against diabetic cardiovascular disease by decreasing TG and [Ga2+], against diabetic nephropathy by decreasing ROS and against diabetic neuropathy by increasing Nrf2. The arrow means the direction of actions, and the black full lines indicate upregulation and red dotted lines refer to downregulation or inhibition. CRP, C-reactive protein; MAPK p38-NIK, NF-κB inducing kinase; LKB1, kelch-like ECH-associated protein-1; EEF2K, eukaryotic elongation factor-2 kinase; ARE, antioxidant-responsive element; GSK-3β, glycogen synthase kinase-3β; IR, insulin resistance; MnSOD, Mn superoxide dismutase; NA, noradrenalin; s6k1, ribosomal protein S6 kinase 1; AC, adenylate cyclase; HSL, hormone-sensitive lipase; TG, triglyceride; FA, fatty acid; GL, glycerinum; GSH, glutathione; GSSH, oxidized glutathione; mTOR, the target of rapamycin; EGCG, epigallocatechin gallate; IKK, IκB kinase; NF-κB, nuclear factor-κB; iNOS, inducible nitric oxide synthase; TNF-α, tumor necrosis factor-α; Nrf2, nuclear factor-erythrocyte-associated factor 2; PI3K, phosphatidylinositol 3-hydroxykinase; Akt, protein kinase B; AMPK, adenylic acid-activated protein kinase; T2DM, type 2 diabetes mellitus; GLUT, glucose transporter type; PKA, protein kinase A; ATP, adenosine triphosphate; cAMP, cyclic Adenosine monophosphate; COMT, catechol-O-methyltransferase, an enzyme responsible for the degradation of noradrenalin.
The effects of tea on diabetes mellitus and its complications by in vitro and in vivo studies.
| Tea Types | Constituents | Diseases Types | Study Types | Models | Dose | Effects | Mechanisms | Ref. |
|---|---|---|---|---|---|---|---|---|
| Green tea | EGCG | Diabetic cardiovascular disease | In vivo | Alloxan-induced diabetic rabbits | 50 mg/kg/day | Improved late endothelial progenitor cells(L-EPCs); | Activated Akt/eNOS pathway | [ |
| EGCG | Diabetic cardiomyopathy | In vivo | Wistar rats | 50 mg/kg/day | Enhanced cardiac function; | ↑ Insulin-like growth factor 1 | [ | |
| EGCG | diabetic neuropathy | In vivo | Male Wistar rats | 0.1% (w/v) | Improved cerebral function. | ↓ Neuronal degeneration | [ | |
| Polyphenols | Diabetic Retinopathy | In vivo | Wistar-Kyoto rats | 5.7 g/kg/day | Protected the retina against glutamate toxicity. | ↓ ROS | [ | |
| Polyphenols | Diabetic cardiovascular disease | In vivo | Male Wistar rats | 0.8, 1.6, and 3.2 g/L | Reduced fat deposit; | ↓ Extracellular signal regulated kinase 1/2 phosphorylation | [ | |
| Polyphenols | Diabetic cardiovascular disease | In vitro | Cardiac muscle of rats | 200 mg/kg | Ameliorated the effects of high-fructose diet on insulin signaling, lipid metabolism and inflammation. | ↑ PI3k, Akt1 | [ | |
| Diabetic cardiovascular disease | In vivo | STZ-induced rats | 300 mg/kg/day | Protected rat heart. | ↓ [Ca2+] and [Na+] | [ | ||
| Diabetic cardiovascular disease | In vivo | STZ-induced rats | 300 mg/kg/day | Reduced the risk of diabetic cardiovascular disease. | ↓ Cholesterol, triglyceride | [ | ||
| Diabetic cardiomyopathy | In vivo | Diabetic rats | 300 mg/kg/day | Treated diabetic cardiomyopathy. | ↓ AGEs | [ | ||
| diabetic retinopathy | In vivo | Rats | 200 mg/kg/day | Prevented and treated diabetic retinopathy. | ↓ SOD and catalase enzyme | [ | ||
| Diabetic hepatopathy | In vivo | Male Wistar rats | 1.5% (w/v) | Prevented diabetic tissue injury. | ↑ GSH-Px, SOD, catalase | [ | ||
| Diabetic hepatopathy | In vivo | Male Wistar rats | 1.5% (w/v) | Pretected tissue. | ↑ GSH-Px, SOD, catalase | [ | ||
| Diabetic nephropathy and hepatopathy | In vivo | Male Sprague-Dawley rats | 0.1% (w/v) | Protected renal and hepatic tissues from injury. | ↑ Total antioxidant levels | [ | ||
| Diabetes mellitus-induced periodontitis | In vivo | STZ-induced rats | N/A | Treated diabetes mellitus-induced periodontitis. | ↓ TNF-α and RANKL | [ | ||
| diabetic spinal cord | In vivo | STZ-induced rats | N/A | Improved diabetic spinal cord. | ↑ GFAP | [ | ||
| Black tea | T1DM | In vivo | Female CD-1 mice | 0.01% (w/v) | Promoted insulin secretion and regenerated damaged pancreas and protected pancreatic β- cells. | ↓ Nitrosative stressRUNX-2, OPG↓ ROS | [ | |
| Diabetes mellitus | In vivo | STZ-induced rats | 0.5 mL/day | Regenerated damaged pancreas and protected pancreatic β-cells. | ↓ Nitrosative stress | [ | ||
| T2DM | In vivo | STZ-induced rats | 0.01 mL/g/day | Ameliorated diabetes mellitus associated oxidative stress. | ↑ GSH | [ | ||
| Diabetic complication | In vivo | Diabetic animals | 50 mg/mL | Attenuated oxidative stress mediated tissue damage. | ↓ DNA fragmentation | [ | ||
| Diabetic tissue injury | In vivo | Adult male Wistar albino rat | 50 and 100 mg/kg/day | Protected the liver | ↑ Cellular antioxidant capacity | [ | ||
| EGC, GC, GCG | bone metabolism | In vitro | Cultured rat osteoblast-like osteosarcoma cell line UMR-106 | N/A | Improved bone metabolism | ↑ Osteoblast activity | [ | |
| White tea | T2DM | In vivo | Male Sprague-Dawley rats | 0.5% (w/v) | Lowered blood sugar levels. | ↑ Insulin sensitivity | [ | |
| Diabetic cardiovascular diseases | In vivo | Male Wistar rats | 0.01 mg/mL | Prevented cardiovascular diseases. | ↑ Insulin sensitivity | [ | ||
| Diabetes mellitus | In vitro | human hepatocellular carcinoma (HepG2) cell | 25 mg/mL | Improved glucose and lipid metabolism. | ↓ Glucose uptake and transport | [ | ||
| Diabetic reproductive dysfunction | In vivo | STZ-induced prediabetic rat model | 10 mg/mL | Improved epididymal sperm motility and restored sperm viability. | ↓ GLUT3 protein | [ | ||
| Dark tea | EGCG, ECG | Diabetes mellitus | In vitro | N/A | 50 mg/mL | Treated diabetes mellitus. | ↓ α-glucosidase | [ |
| TP,TPS | Diabetes mellitus | In vivo | Diabetic rats | 50 mg/kg | Reduced postprandial blood sugar. | ↓ α-glucosidase | [ | |
| Polysaccharides | T2DM | In vivo | Male ICR mice | 40 mg/kg | Lowered the blood glucose levels and reversed oxidative stress. | ↑ SOD activity | [ | |
| T2DM | In vivo | Male ICR mice | 1 and 5 mg/kg | Improved insulin resistance. | ↓ α-glucosidase | [ | ||
| T2DM | In vitro | HepG2 cells | 100, 200, and 400 mg/kg/day | Improved insulin resistance and maintained glucose homeostasis. | ↑ Glucose uptake | [ | ||
| T2DM | In vivo | Male Sprague−Dawley rats | 400 mg/kg/day | Alleviated insulin resistance and chronic kidney disease. | ↓ SIRP-α | [ | ||
| diabetic nephropathy | In vivo | db/db mice and db/m mice | 1 g/kg/day | Attenuated the increases in urinary albumin, serum creatinine, and mesangial matrix. | ↓ AGEs | [ | ||
| Onloog tea | Polysaccharide | diabetic tissue and kidney | In vivo | STZ-induced diabetic diabetic mice | 50, 100, and 200 mg/kg | Prevented diabetic tissue and kidney diseases. | ↑ SOD and GSH-PX activity | [ |
| Polysaccharide | Diabetic immune disease | In vivo | STZ-induced diabetic mice | 100, 300, and 600 mg/kg in mice | Improved immunomodulatory function. | ↑ The activity of NK cellsIntensify DTH | [ | |
| Yellow tea | EGCGGCG | Diabetes mellitus | In vitro | N/A | 1% (w/v) | CGC reduced postprandial blood sugar more effectively. | ↓ α-glucosidase | [ |
| Diabetic complications | In vivo | db/db mice | N/A | Lowered the serum total and low-density lipoprotein cholesterol and triglyceride levels. | ↓ The lipid synthesis | [ | ||
| Tea | EGCG | T1DM | In vitro | RINm5F cells | 20-40 | Protected pro-inflammatory cytokine and induced injuries in insulin-producing cells. | ↓ iNOS and NO | [ |
| T1DM | in vivo | C57BL/KsJ mice | 100 mg/kg/day | Protected pancreatic islets. | ↓ iNOS | [ | ||
| EGCG | T2DM | In vivo | Diabetic patients | 300, 600, and 900 mg/day | Decreased pathogenesis of proinflammation and improved diabetes mellitus. | ↓ Free radicals | [ | |
| Catechins | T2DM | In vivo | Male obese KK-ay and C57BL/6J mice; | 20 mg/kg/day | Decreased glucose levels and increased glucose tolerance in animals. | ↓ ROS | [ | |
| EGCG | T2DM | In vitro | Human HepG2 cells | N/A | Attenuated insulin signaling blockade. | ↓ Phosphorylation of IRS-1 | [ | |
| EGCG | T2DM | In vivo | Sprague-Dawley rats | 1-100 | Improved endothelial dysfunction and insulin resistance and protected against myocardial I/R injury. | ↑ NO via PI3k pathway | [ | |
| diabetic nephropathy | In vivo | Diabetic SHR rats | 5.7 g/kg/day | Reduced podocyte apoptosis, foot process effacement and albuminuria. | ↓ GSK3-p53 | [ | ||
| diabetic nephropathy | In vivo | STZ-induced diabetic rats | 5% (w/v) | Improved diabetic nephropathy. | ↓ MMP-9, TIMP-1 | [ | ||
| diabetic nephropathy | In vivo | Male Sprague-Dawley rats | 0.25% and 0.5% (w/w) | Reduced renal oxidative damage and inflammatory reactions. | ↑ Activity of 5′-lipoxygenase | [ | ||
| Catechins | diabetic nephropathy | In vivo | Sprague-Dawley rats | 0.25% and 0.5% (w/w) | Improved kidney function. | ↓ Thromboxane A(2) synthesis | [ |
Abbreviations: iNOS, inducible nitric oxide synthase; RANKL, receptor activator of nuclear factor kappa-B ligand; OPG, osteoprotegerin; RUNX-2, runt-related transcription factor 2; GFAP, glial fibriliary acidic protein; SRET, sterol regulatory element-binding transcription factor 1; SREP, synthase and sterol response element-binding protein; TIMP, tissue inhibitor of metalloproteinases; STZ, streptozotocin; SHR, spontaneous hypertension rat, ICR, Institute of Cancer Research; Akt, protein kinase B; eNOS, endothelial nitric oxide synthase; PPARγ, peroxisome proliferator-activated receptorγ; PI3K, phosphatidylinositol 3-hydroxykinase; GLUT, glucose transporter type; GSK-3β, glycogen synthase kinase-3β; TNF, tumor necrosis factor; AGEs, advanced glycation end products; SOD, superoxide dismutase; GSH-Px, glutathione peroxidase; SIRP, signal regulatory protein; Nrf2, nuclear factor-erythrocyte-associated factor 2; mTOR, the target of rapamycin; S6k1, ribosomal protein S6 kinase 1; JNK, jun NH2-terminal kinase; w/v, weight/volume; w/w, weight/weight.
Figure 3The association between tea and diabetes and its complications. Tea has effects on type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) by protecting pancreatic β-cells and ameliorating insulin resistance. Besides, due to the anti-inflammatory and antioxidant properties of tea, diabetic complications, including diabetic cardiovascular complication, diabetic nephropathy, diabetic neuropathy, and diabetic hepatic tissue injury, could be prevented and treated by tea and its bioactive components.
The effects of tea on diabetes mellitus and its complications based on clinical trials.
| Tea Types | Diseases Types | Study Types | Participants | Dose and Duration | Results | Ref. |
|---|---|---|---|---|---|---|
| Green tea | Diabetes mellitus | RCT | Patients with T2DM (N = 63) | 0, 2, 4 cups per day | ↓ Body weight, body mass index, waist circumference and systolic blood pressure. | [ |
| Green tea | Diabetes mellitus and diabetic nephropathy | RCT | Patients with diabetes mellitus (N = 60) | 2 capsules containing 1120 mg polyphenols per day for 20 weeks. | No significant effect on diabetes mellitus and diabetic nephropathy. | [ |
| Green tea | T2DM and diabetic cardiomyopathy | RCT | Subjects with T2DM and lipid abnormalities (N = 92) | 500 mg per day | ↓ Triglyceride | [ |
| Green tea | Diabetic osteoporosis | RCT | Patients with diabetes mellitus (N = 35) | 1120 mg polyphenols per day | ↑ Bone mineral content | [ |
| Green tea | Bone turnover induced by diabetes mellitus | RCT | Patients with T2DM (N = 72) | 500 mg per day | ↓ Fasting serum osteocalcin | [ |
| Black tea | T2DM and diabetic cardiovascular | N/A | Patients with T2DM (N = 46) | 150, 300, 450, and 600 mL black tea during the weeks 1, 2, 3 and 4. | ↓ Serum malondialdehyde | [ |
| Oolong tea | T2DM | N/A | Patients with T2DM | 1500 mL per day | ↓ Concentrations of plasma glucose and fructosamine | [ |
| Green and black tea | T2DM | RCT | White persons (N = 49) | 0, 375, or 750 mg per day for 3 months | No significant effect on T2DM. | [ |
N/A, not available; RCT, randomized, controlled clinical trial; FBG, Fasting blood glucose; T2DM, type 2 diabetes mellitus; PTH, parathyroid hormone; HbA1C, hemoglobin A1c.